Cobra Biologics, a contract biologics manufacturer, has been contracted to develop a second cell line for Alligator Bioscience AB, a Swedish biotechnology company.

Alligator has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a master cell bank (CHO-S) and chemically defined media.

In May 2015 Cobra released details of it's involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator's Phase I trial in advanced solid tumors.

Source: Cobra Biologics